Meet Maria Miranda – The Heartbeat of Patient Advocacy
Maria is more than a patient advocate she is a guardian of comfort and a champion of care
Related Articles
Preliminary Efficacy, Safety Data Drive Further Exploration of Mezigdomide-Based Combinations in R/R Myeloma
David S. Siegel, MD, PhD, discusses early safety and efficacy data that support further development of mezigdomide-based combinations in multiple myeloma.
Isatuximab Plus VRd Wins EU Approval for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
The EMA’s CHMP has approved isatuximab in combination with VRd for transplant-ineligible patients with newly diagnosed multiple myeloma.
Second Cycle of Medicare Drug Price Negotiations Includes 4 Oncologic Agents
The CMS has selected 15 drugs covered under Medicare Part D for the second cycle of the Drug Price Negotiation Program, including enzalutamide, pomalidomide, palbociclib,…
2024 FDA Approvals Highlight New Treatment Considerations in HR+ Breast Cancer
Eric Winer, MD, discusses the significance of 2 FDA approvals for HR-positive, HER2-negative breast cancer and emerging novel breast cancer treatments.
UGN-102 Shows Favorable Risk-Benefit Profile, Sustained CR Rates in Low-Grade, Intermediate-Risk NMIBC
Durable responses with UGN-102 signal its viability as a nonsurgical alternative to TURBT in low-grade, intermediate-risk NMIBC.
Acute myeloid leukemia with BCL6 and KMT2A dual rearrangements
A 2-year-old boy was diagnosed with acute myeloid leukemia (AML) with t(10;11)(p12.31;q23.3)/ KMT2A:: MLLT10 rearrangement. Despite 5 lines of treatment, including a menin inhibitor and…
Dr Al Malki on Reducing Relapse Risk in Patients Undergoing Haplo-HSCT
Monzr M. Al Malki, MD, discusses reducing relapse risk in patients undergoing haploidentical hematopoietic stem cell transplantation.
LaCasce on Bispecific Antibodies Transforming Lymphoma Care
Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.
Everolimus Plus Lanreotide Extends PFS in Advanced GEP-NETs
Everolimus plus lanreotide demonstrated an improved PFS compared with everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.